SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is generating intense discussion after discontinuing its compounded semaglutide pill amid regulatory pressure from the FDA and DOJ. The community is sharply divided, with some viewing it as a strategic retreat to battle "Big Pharma" for affordable GLP-1 access, while others see it as a significant blunder threatening trust and future growth.

OpenAI pioneers large-language models like GPT and DALL·E, enabling advanced AI applications. Their research emphasizes both cutting-edge capability and responsible deployment strategies.

OpenAI PreStocks

OPENAI CRYPTO is trending due to widespread community discussion and strong warnings that it is an unofficial, unaffiliated cryptocurrency attempting to capitalize on the high investor interest in the legitimate OpenAI company's pre-IPO valuation. Many users are raising concerns about its legitimacy and potential for being a scam, despite the genuine demand for access to high-profile private AI companies.

HOPPY is a memecoin launched on Ethereum as a tribute to the frog from the famous comic book «The Night Riders», published in 2012 by artist and illustrator Matt Furie, which has gained popularity.   HOPPY appeals to the cryptocurrency community with its no-tax policy and transparent acknowledgment of its lack of utility, maintaining the essence of a pure and simple memecoin.

Hoppy

HOPPY is gaining momentum as the "second frog" in the popular "three frog narrative" alongside $PEPE and $FEFE, with the community aggressively accumulating on dips, anticipating massive gains, and speculating on major exchange listings despite ongoing discussions about the correct token contract.

Dollar General Corp. engages in the operation of merchandise stores. Its offerings include food, snacks, health and beauty aids, cleaning supplies, basic apparel, housewares, and seasonal items. It sells brands including Clorox, Energizer, Procter & Gamble, Hanes, Coca-Cola, Mars, Unilever, Nestle, Kimberly-Clark, Kellogg's, General Mills, and PepsiCo. The company was founded by J. L. Turner and Hurley Calister Turner Sr. in 1939 and is headquartered in Goodlettsville, TN.

Dollar General Corp.

Dollar General is trending following strong earnings that beat expectations, fueled by successful store remodels and effective shrink reduction, positioning it as a key beneficiary of consumer trade-down to value-oriented shopping amidst economic uncertainty.

OpGen, Inc. is a precision medicine company, which engages in the power of molecular diagnostics and informatics to help combat infectious disease. It focuses on the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Clarksburg, MD.

Opgen Inc

OPGN is trending as the community buzzes over its strategic pivot to an AI-enabled fintech company, evidenced by recent financial filings showing revenue from its CapForce platform and the iCapX acquisition. Speculation about an imminent Nasdaq relisting and the stock's extremely low float is fueling discussions of a potential short squeeze.

Pepe the Frog has become a global symbol of love and unity, bringing together a vast and passionate community. Created by artist Matt Furie, Pepe continues to inspire culture across the internet. Notably, Furie designed a rare 1-of-1 NFT featuring Donald Trump and Pepe together — a unique fusion of art and meme history. Donald Trump himself has embraced the Pepe meme, sharing it in posts dating back to 2015 and even as recently as 2025.

Trump Pepe

TRUMPE CRYPTO is trending as a meme coin combining the popular $PEPE theme with Donald Trump, sparking community debate between those seeing it as a significant opportunity and others cautioning against it as another potential politically-themed "scam" token.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp. - Warrants (30/06/2028)

Trump Media & Technology Group Corp. - Warrants (25/03/2029)

DJTWW warrants are seeing heightened activity and extreme volatility following news of stock warrant exercises generating significant cash proceeds for Trump Media, polarizing community sentiment between expectations of major gains tied to political developments and strong warnings of high risk.

SSgA Active Trust - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

The Technology Select Sector SPDR Fund (XLK) is trending as the community debates its narrow market leadership amid signs of weakening sector breadth and a rotation into value, despite robust earnings forecasts and significant institutional buying in key mega-cap components like semiconductors.

Sei is a high-performance Layer 1 blockchain that scales the EVM with parallelized execution, enabling faster transactions, low fees, and seamless smart contract deployment. Sei removes traditional blockchain bottlenecks while maintaining full Ethereum compatibility. The upcoming Giga upgrade will deliver 50x improvements in EVM throughput, optimizing execution, consensus, and storage to push blockchain performance to web2 levels.

SEI is trending amid strong community discussion about its undervaluation and potential for significant growth, fueled by recent developments like its Xiaomi partnership, Ondo Finance's USDY integration, and an ETF filing, positioning it as a key Layer-1 for Real World Assets and AI.

CACI International, Inc. is a holding company, which engages in the provision of information solutions and services in support of national security missions and government transformation for intelligence, defense, and federal civilian customers. It operates through the Domestic Operations and International Operations segments. The Domestic Operations segment offers information solutions and services to U.S. federal government agencies, state and local governments, and commercial enterprises to different market areas, including business systems, command and control, communications, cyber security, enterprise information technology, health, intelligence services, investigation and litigation support, logistics and material readiness, and surveillance and reconnaissance. The International Operations segment includes the provision of IT services and proprietary data and software products, serving commercial and government customers. The company was founded by Herb Karr and Harry Markowitz in July 1962 and is headquartered in Reston, VA.

Caci International Inc. - Registered Shares - Class A

CACI International is trending due to its significant acquisition of ARKA Group, bolstering its national security and space capabilities, alongside a flurry of analyst upgrades and continuous government contract wins. The community is actively debating whether this growth offsets recent mixed earnings and broader concerns over government spending, with many highlighting CACI's resilient, mission-critical defense and IT services.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Roivant Sciences (NASDAQ:ROIV) Reaches New 1-Year High - Still a Buy?

Roivant Sciences (NASDAQ:ROIV) Sets New 52-Week High - What's Next...

Roivant Sciences Q3 Earnings Call Highlights

Roivant Sciences (NASDAQ:ROIV) executives highlighted new Phase II results for brepocitinib in cutaneous sarcoidosis, along with a set of broader clinical and corporate milestones, during the...

Roivant Sciences Stock Rises 17% Over Positive Data From Phase 2 Study Of Brepocitinib

(RTTNews) - Shares of Roivant Sciences Ltd. (ROIV) are climbing about 17 percent on Friday morning trading over the announcement of positive results from the Phase 2 study of brepocitinib in...

Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates

Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of +9.43% and -67.32%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

<ul class="summary-bullets"><li>In the BEACON study, patients receiving the higher 45 mg dose of brepocitinib saw substantial reductions in skin disease activity.</li><li>The trial enrolled 31 participants across U.S. clinical sites and tested two dose levels against a placebo.</li><li>Following discussions with the U.S. Food and Drug Administration, Roivant’s subsidiary,&nbsp;Priovant, plans to launch a pivotal Phase 3 study in cutaneous sarcoidosis in 2026.</li></ul>Roivant Sciences (ROIV) on Friday reported encouraging Phase 2 clinical results for its experimental oral therapy brepocitinib in adults with cutaneous sarcoidosis, while also releasing its fiscal third quarter (Q3) earnings.&nbsp;The company reported a Q3 revenue of $1.9 million and a loss per share (EPS) of $0.38. Revenue came in below the analysts’ consensus estimate of $6.14 million, while EPS surpassed the consensus, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">Positive BEACON Trial Outcomes&nbsp;</h2>In the BEACON study, patients receiving the higher 45 mg dose of brepocitinib saw substantial reductions in skin disease activity compared with placebo, demonstrating statistically meaningful benefits as early as four weeks and maintained through week 16.The trial enrolled 31 participants across U.S. clinical sites and tested two dose levels against a placebo. Despite including the most treatment-resistant patients, the highest-dose group achieved rapid and sustained improvement.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/ROIV">Roivant stock</a> traded over 9% higher in Friday’s pre-market.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘normal’ message volume levels.&nbsp;<h2 class="st-heading-2">Updates On Subsidiaries’ Therapy Programs</h2>Following discussions with the U.S. Food and Drug Administration (FDA), Riovant’s subsidiary, Priovant, plans to launch a pivotal Phase 3 study in cutaneous sarcoidosis in 2026. The company has already submitted a New Drug Application for brepocitinib in dermatomyositis and expects additional Phase 3 data in non-infectious uveitis during the second half of 2026.Additionally, the company said Immunovant’s IMVT-1402 program is fully enrolled in a late-stage rheumatoid arthritis study, with results anticipated in 2026.&nbsp;Meanwhile, the firm’s subsidiary Pulmovant’s&nbsp;mosliciguat trial in pulmonary hypertension linked to interstitial lung disease is also fully enrolled.As of Dec. 31, 2025, Roivant reported approximately $4.5 billion in cash andequivalents.ROIV stock has gained over 94% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-looks-to-end-a-five-day-losing-streak-retail-believes-the-next-growth-wave-is-unfolding-now/cZbFfdXR4nD">Nvidia Looks To End A Five-Day Losing Streak – Retail Believes ‘The Next Growth Wave Is Unfolding Now’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Roivant Sciences logo is seen displayed on a smartphone screen.

Why Did Roivant Sciences Stock Gain 9% Pre-Market Today?

The company reported the Phase 2 clinical results for its experimental oral therapy brepocitinib, along with third-quarter financial data. 

Equity

The company reported the Phase 2 clinical results for its experimental oral therapy brepocitinib, along with third-quarter financial data. 


Insights into Roivant Sciences Q3 Earnings

Roivant Sciences (ROIV) to Release Quarterly Earnings on Friday

Roivant Sciences (NASDAQ:ROIV) will be releasing its Q3 2026 earnings before the market opens on Friday, February 6. (View Earnings Report at...

Parkside Financial Bank & Trust Has $10.57 Million Holdings in Roivant Sciences Ltd. $ROIV

Parkside Financial Bank & Trust trimmed its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 46.7% in the third quarter, according to its most recent Form 13F filing with the Securities...

Campbell & CO Investment Adviser LLC Sells 68,705 Shares of Roivant Sciences Ltd. $ROIV

Campbell & CO Investment Adviser LLC trimmed its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 65.8% during the third quarter, according to its most recent disclosure with the...

Eric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the company's stock in a transaction that occurred on Monday, January 12th. The stock was sold at an...

$ROIV Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.38
• Reported revenue of $2M

Stocktwits

Roivant Sciences Ltd

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.38
• Reported revenue of $2M

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

What will be the S&P 500’s next 5% move?

ROIV
Roivant Sciences Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Earnings Recap

Latest ROIV News

ROIVRoivant Sciences Ltd